Daniel Devine & Co’s Pfizer PFE Stock Holding History

Daniel Devine & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$1.98M	Sell	57,400 -5,059	-8%	-$173K	1.58%	14
2018 Q1	$2.1M	Sell	62,459 -425	-0.7%	-$14.6K	1.71%	13
2017 Q4	$2.16M	Sell	62,884 -685	-1%	-$23.4K	1.56%	13
2017 Q3	$2.15M	Hold	63,569	–	–	1.65%	12
2017 Q2	$2.03M	Sell	63,569 -8,879	-12%	-$280K	1.65%	12
2017 Q1	$2.35M	Sell	72,448 -8,346	-10%	-$263K	1.93%	11
2016 Q4	$2.49M	Sell	80,794 -106	-0.1%	-$3.24K	1.77%	14
2016 Q3	$2.6M	Hold	80,900	–	–	1.75%	16
2016 Q2	$2.7M	Hold	80,900	–	–	1.84%	14
2016 Q1	$2.27M	Buy	80,900 +27,854	+53%	+$796K	1.48%	17
2015 Q4	$1.63M	Hold	53,046	–	–	1.07%	26
2015 Q3	$1.58M	Hold	53,046	–	–	1.12%	25
2015 Q2	$1.69M	Hold	53,046	–	–	1.16%	23
2015 Q1	$1.75M	Buy	53,046 +5,692	+12%	+$181K	1.17%	24
2014 Q4	$1.4M	Buy	+47,354	New	+$1.36M	1%	27

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Daniel Devine & Co's PFE Position: Q2 2018 in Review

Daniel Devine & Co reduced its Pfizer (PFE) stake by 8.1% in Q2 2018, selling an estimated $173K and leaving 57,400 shares worth $1.98M. The position accounts for 1.58% of the portfolio, ranked #14.

Daniel Devine & Co first reported a position in PFE in Q4 2014 and has held it in 15 quarters since. The position peaked at $2.7M in Q2 2016. 2,205 funds tracked by Wall St. Rank hold PFE as of Q2 2018.

Daniel Devine & Co held 57,400 shares of Pfizer worth $1.98M as of Q2 2018.
Daniel Devine & Co sold 5,059 Pfizer shares in Q2 2018, an estimated $173K.
Pfizer made up 1.58% of Daniel Devine & Co's portfolio in Q2 2018, its #14 holding.
Daniel Devine & Co first reported a position in Pfizer in Q4 2014 and has held it in 15 quarters since.
Daniel Devine & Co's Pfizer position peaked at $2.7M in Q2 2016.
2,205 funds tracked by Wall St. Rank held Pfizer as of Q2 2018.

Based on Daniel Devine & Co's 13F filing for Q2 2018, filed 18 Jul 2018.